Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently
identified autoimmune disorder that presents in both adults and children as CNS …

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the
most recently defined inflammatory demyelinating disease of the central nervous system …

The term 'neuromyelitis optica spectrum disorders'(NMOSD) is used as an umbrella term that
refers to aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica (NMO) …

In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …

Infusion of T cells engineered to express chimeric antigen receptors (CARs) that target B
cells has proven to be a successful treatment for B cell malignancies. This success inspired …

This manuscript presents practical recommendations for managing acute attacks and
implementing preventive immunotherapies for neuromyelitis optica spectrum disorders …

The realization that autoantibodies can contribute to dysfunction of the brain has brought
about a paradigm shift in neurological diseases over the past decade, offering up important …

Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central
nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis …

Background IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-
mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B …

Background Satralizumab, a humanised monoclonal antibody targeting the interleukin-6
receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder …